Xilio Therapeutics, Inc. Common Stock
XLOXilio Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies. The company aims to harness the immune system to target and destroy cancer cells, with a pipeline centered on tumor-selective cytokine therapies. Founded to advance precision immunotherapy, Xilio aims to improve treatment outcomes for patients with solid tumors.
Company News
Xilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.
Xilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapit...
Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.
Xilio Therapeutics announced updated Phase 2 data for its tumor-activated anti-CTLA-4 drug vilastobart in combination with atezolizumab, showing a 26% preliminary objective response rate in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases.
Xilio Therapeutics reported progress in its pipeline, including positive initial Phase 2 data for its tumor-activated anti-CTLA-4 therapy vilastobart in metastatic microsatellite stable colorectal cancer. The company also announced a collaboration with AbbVie to develop novel tumor-activated immunotherapies.
